A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent
Elizabeth Garrett‐Mayer and
Journal of the Royal Statistical Society Series C, 2021, vol. 70, issue 5, 1210-1229
Immunotherapy is an innovative treatment approach that harnesses a patient’s immune system to treat cancer. It has provided an alternative and complementary treatment modality to conventional chemotherapy. Combining immunotherapy with cytotoxic chemotherapy agent has become the leading trend and the most active research field in oncology. To accommodate this growing trend, we propose a Bayesian phase I/II dose‐finding design to identify the optimal biological dose combination (OBDC), defined as the dose combination with the highest desirability in the risk‐benefit trade‐off. We propose new statistical models to describe the relationship between the doses and treatment outcomes, including immune response, toxicity and progression‐free survival (PFS). During the trial, based on accrued data, we continuously update model estimates and adaptively assign patients to dose combinations with high desirability. The simulation study shows that our design has desirable operating characteristics.
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:bla:jorssc:v:70:y:2021:i:5:p:1210-1229
Ordering information: This journal article can be ordered from
http://ordering.onli ... 1111/(ISSN)1467-9876
Access Statistics for this article
Journal of the Royal Statistical Society Series C is currently edited by R. Chandler and P. W. F. Smith
More articles in Journal of the Royal Statistical Society Series C from Royal Statistical Society Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().